The Discounted Cash Flow (DCF) valuation of Esperion Therapeutics Inc (ESPR) is (2.76) USD. With the latest stock price at 0.87 USD, the upside of Esperion Therapeutics Inc based on DCF is -417.5%.
Based on the latest price of 0.87 USD and our DCF valuation, Esperion Therapeutics Inc (ESPR) is a sell. selling ESPR stocks now will result in a potential gain of 417.5%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.2% - 6.8% | 6.0% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (15.38) - (1.94) | (2.76) |
| Upside | -1866.3% - -323.1% | -417.5% |